A Phase I Study of Compound 506U78 (NSC #686673) in Patients With Hematologic Malignancies and Renal or Hepatic Impairment
Phase of Trial: Phase I
Latest Information Update: 03 Sep 2015
At a glance
- Drugs Nelarabine (Primary)
- Indications Haematological malignancies
- Focus Adverse reactions
- 01 Apr 2011 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 11 Oct 2005 New trial record.